Drug intelligence / Profile preview

Yiqing Zhuyun Formula II

Development stage: Unknown
Lead developer: Chengdu University of Traditional Chinese Medicine
Administration: Oral

Overview

Yiqing Zhuyun Formula II is a Traditional Chinese Medicine (TCM) formula primarily investigated for its potential to improve pregnancy outcomes in women experiencing recurrent implantation failure (RIF). Research suggests it may exert its therapeutic effects by modulating the immune system, specifically by balancing cytokines involved in maternal-fetal immune tolerance. The T-cell receptor signaling pathway has been implicated in its pharmacological activity.

Other names: 中药怡情助孕II号方Zhuyun FormulaZYF

Beyond the preview

Go deeper on Yiqing Zhuyun Formula II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiqing Zhuyun Formula II.

Explore the full profile